I've carried this category in my project list for some time: medications and compounds that work against the mainstream pharmaceutical narrative. Cutting-edge, often regulatorily ambiguous, frequently more effective for specific use-cases than what big pharma puts forward — but underserved by the marketing machinery because of it.
Internal taxonomy: Organic-Led Pharmaceuticals. The "organic-led" qualifier captures that these are either plant-derived, naturally occurring metabolic compounds, biological repurposing of approved drugs, or peptide-class molecules — distinct from purely synthetic mainstream pharma. The full canvas at the start of the project list:
The two regulatory windows opening simultaneously (Trump psychedelic EO April 2026, DOJ cannabis Schedule III order April 2026, FDA peptide reclassification April 2026, July PCAC meeting) are why this category goes from "watching brief" to "build now."
Before walking through the canvas, three load-bearing facts that shape every recommendation below:
Ranked rough cash-flow tier × defensibility × regulatory headroom. Detailed evidence per candidate in the source forager reports.
Six foragers + the existing Proven Longevity / Proven Nootropics assets surface a clear three-vehicle structure. Bundling everything under a single brand would contaminate the clinical-clean positioning that the Proven family already holds, and would expose clean-channel ventures to the payment-processor and ad-platform restrictions that the grey-area and cannabis ventures face. Three vehicles, clean separation:
| Sibling | Status | Compounds covered |
|---|---|---|
| Proven Longevity | Existing | Rapamycin (flagship), oral NMN, senolytics, metformin-bundled, longevity peptides |
| Proven Nootropics | Existing | Cognitive enhancement compounds |
| Proven Metabolic | NEW | GLP-1 branded (Wegovy / Mounjaro / Zepbound), GLP-1 telehealth, metabolic interventions |
| Proven Hormones | NEW | TRT, enclomiphene, HCG, men's hormone optimisation. Women's HRT possible Phase 3 sibling. |
| Proven Psyche | NEW | Ketamine telehealth aggregator, psilocybin (Oregon/Colorado dir, Compass-watching), microdosing courses, MDMA watching-brief vertical |
| Proven Botanicals | NEW | Terpenes, premium CBD/CBG/CBN/CBC, kanna, kava (US-only), blue lotus, functional botanicals |
| Brand / Sub-brief | Status | Substance |
|---|---|---|
| Ibogaine Bridge | PARENT (briefed) | Mexico ibogaine clinic referral |
| Peptide Bridge | BOLT-ON (briefed) | Telehealth peptide clinic referral + select vendor affiliate |
| 5-MeO + Ayahuasca Bridge | NEW (Tier 2) | Mexico/Peru/Costa Rica retreat referral (Tandava, Rythmia, Soltara, Behold) |
| Methylene Blue Bridge | NEW (Tier 2) | US-only methylene blue affiliate (Troscriptions, BlueBrainBoost). UK geo-blocked. |
| NAD+ Bridge (optional) | NEW (Tier 3) | Injectable NAD+ telehealth (compounded, Rx) |
| Sub-brand | Status | Market |
|---|---|---|
| Cannabis Compass UK | NEW (Tier 1) | UK medical cannabis clinic referral (Releaf, Sapphire, Mamedica, Curaleaf UK) |
| Cannabis Compass US | NEW (Tier 2) | US medical cannabis card services (NuggMD, Veriheal, Leafwell) |
| Hemp Cliff Explainer | NEW (sunset-only) | Single hub funnelling Nov 2026 novel-cannabinoid sunset traffic to medical referral. No standalone brand. |
Ranked by cash flow × defensibility × regulatory headroom. Tier 1 ventures launch within 30 days. Tier 2 follow at Months 3–6 once Tier 1 is cash-positive. Tier 3 ventures are roadmap items that may be deprioritised depending on Tier 1 outcomes.
Biggest single drug category in history. Post-compounding-shutdown shake-out (Apr 2025) thinned competitors. Affiliate to Hims, Ro, LifeMD, Henry Meds, Form, Sequence. $50–$150 CPA. Long-tail SEO defensible on drug interactions, side-effects, comparison content. UK angle via private GP referrals (Numan, Juniper UK).
262% market growth 2022→2024. 80K active patients. Public still largely unaware UK medical cannabis is legal since 2018 — massive education gap = content moat. £30–£100 per qualified patient referral to Releaf + Sapphire + Mamedica. Higher AOV than US side, less regulatory volatility.
$1,800–$5,400/yr LTV. $100–$300 CPA. Marek Health, Maximus, Hone Health, Defy as partners. Seventh Circuit ruling makes marketing-services structure defensible. Strongest unit economics alongside GLP-1.
Largest active TAM in psychedelics. Saturated provider side, under-served aggregator/comparison side. Mindbloom, Joyous, Better U partner programs (direct BD required for terms). $50–$200/lead, $200–$500/conversion. AKS-safe under marketing-services structure.
Highest per-conversion economics of the Tier 1 set ($1,500–$2,200). Trump EO + Rogan + Texas IMPACT + Stanford study + VETS pipeline. Mexico-operator seat would be filled by Patrick if onboarded — his existing pharma middleman position is the natural profile match. Full brief →
Rythmia $1,500/booking with 365-day cookie is the highest-paying affiliate identified across the entire canvas. Mexico (5-MeO) + Costa Rica/Peru (ayahuasca) retreat referral. Shares the Mexico-operator seat with Ibogaine Bridge — Patrick would extend his clinic-side work naturally into this venture.
Smaller per-conversion economics ($30–$60 affiliate, $50–$150 lead). Strategic value is the audience overlap with ibogaine + the bolt-on relationship to the Bridge family operating pattern. Venture prompted by Keys (mutual contact); a defined operational lane (e.g. newsletter / community ops) is a possible role-fit for him if interested. Full brief →
The only lane that's payment + ad processor clean AND scales to product ownership (private-label kanna blends, terpene formulations). 15–25% affiliate on KA! Empathogenics + adjacents. Long-term equity play once Tier 1 cash-positive.
5× Google Trends growth 2024→2025. RFK Jr./Rogan/Huberman amplification. Troscriptions affiliate is the cleanest position (pharma-grade, third-party tested). UK MHRA hard-stop → geo-block UK traffic. Treat as CAC engine for the Bridge family rather than brand-builder.
$18–$25 CPA via NuggMD/Veriheal × state-by-state SEO scale. DOJ Schedule III is a 2026 tailwind. Build once UK Cannabis Compass is cash-positive.
Compass Pathways FDA decision late-2026/early-2027 reshapes the economics. Build the directory + integration coach marketplace in advance; pivot to clinical channel post-approval.
Terpene therapeutic formulations (limonene anxiety, myrcene sleep) + premium CBG/CBN/CBC affiliate. Sub-hubs of Proven Botanicals once kanna anchor is live.
Injectable NAD+ via compounded prescription telehealth (Sprout Health, Palm Beach Labs, HydraMed). Oral NMN folds into Proven Longevity; injectable warrants the Bridge family due to compounding-grey-zone status post-FDA Dec 2024 enforcement memo.
Mt Sinai Phase 3 trial active. High LTV recovery audience but also highest FDA/FTC enforcement attention. Defer until compliance infrastructure hardens — clinical-trial recruitment partnerships could be the unique revenue line (underexploited in this corner).
These compounds got researched in the canvas but DON'T warrant standalone ventures. They deepen the existing brand assets instead.
What each venture needs filled, where the operator sits, and which roles still need a partner. Equity intent flagged per role; specific terms TBD in conversation with whoever fills each seat.
| Venture | the research operation provides | Outstanding operator seat | Identified target |
|---|---|---|---|
| Proven Metabolic (GLP-1) | Research desk, content engine, SEO, site build, automation | US affiliate / telehealth BD relationships (helpful, not required to launch) | None identified yet |
| Cannabis Compass UK | UK regulatory research, content engine, SEO, site build | UK clinic BD outreach (helpful, not required for launch) | None identified yet |
| Proven Hormones (TRT) | Research, content engine, SEO, US telehealth landscape mapping | US clinic BD relationships (helpful) | None identified yet |
| Proven Psyche (Ketamine) | Research, content engine, SEO, AKS-structuring guidance | US telehealth aggregator BD (helpful) | None identified yet |
| Ibogaine Bridge | Research, editorial site, SEO, regulatory monitoring, cardiac-safety editorial discipline | Foundational: Mexico-based clinic-side BD + Spanish-language outreach + in-country verification visits | Patrick — Mexico pharma middleman; existing relationships in adjacent supply chain; profile match for the operator seat |
| 5-MeO + Ayahuasca Bridge | Same as Ibogaine Bridge (shared editorial infrastructure) | Foundational: Mexico + Costa Rica + Peru retreat relationships (Tandava, Rythmia, Soltara, Behold) | Patrick — natural extension of the Ibogaine Bridge operator seat |
| Peptide Bridge | Research, editorial site, SEO, AKS-structuring guidance for telehealth retainer contracts | Operational-lane runner (newsletter + email funnels, OR community ops); optionally a US telehealth BD lead | Keys — venture prompted by him; possible operational-lane fit if interested |
| Proven Botanicals | Research, content engine, SEO, private-label roadmap if pursued | Sourcing relationships for kanna / botanical supply (if private-label pursued) | Patrick (Mexico botanical sourcing) — possible secondary fit, lower priority than Bridge seats |
| Methylene Blue Bridge | Research, US-only site, geo-blocking infrastructure, Troscriptions affiliate setup | None required — the operator can run solo as CAC engine | — |
Capital splits into two tranches per venture: Phase 1 (launch) deploys at Month 1 — entity, infrastructure, UK basic legal review, site build. Phase 2 (ramp) deploys at Month 3 — US healthcare attorney review (AKS structuring for affiliate / telehealth retainer contracts), in-country travel where required, native ad test budget. Phase 2 is gate-tied to real-pipeline traction; not deployed speculatively.
| Venture | Phase 1 (launch, Month 1) | Phase 2 (ramp, Month 3+) | 6-month total |
|---|---|---|---|
| Proven Metabolic | £1,800–£2,800 | £2,000–£4,500 | £3,800–£7,300 |
| Cannabis Compass UK | £2,200–£3,400 | £2,500–£5,500 | £4,700–£8,900 |
| Proven Hormones | £1,800–£2,800 | £2,500–£5,000 | £4,300–£7,800 |
| Proven Psyche (Ketamine) | £2,000–£3,200 | £4,500–£9,000 | £6,500–£12,200 |
| Ibogaine Bridge | £2,200–£3,800 | £4,500–£9,500 | £6,700–£13,300 |
| Tier 1 total (5 ventures) | £10,000–£16,000 | £16,000–£33,500 | £26,000–£49,500 |
Phase 2 legal can be partially consolidated — a single US healthcare attorney engagement covering Ibogaine + Peptide Bridge entities together rather than per-venture saves £4,000–£8,000 in legal spend. Reflected in the per-venture ranges above is the un-consolidated worst case. In-country operating expenses for the Mexico-operator seat are not in this table (sit with operator's seat contribution — see methodology callout).
What's required (per the table above) is documented; who funds it is open. Working options:
For the four Tier 1 ventures without detailed sub-briefs (Proven Metabolic, Cannabis Compass UK, Proven Hormones, Proven Psyche), the Phase 1 / Phase 2 figures above are estimates pending detailed line-item briefs — derived from the same unit-cost basis as Ibogaine / Peptide but not yet verified against venture-specific legal scope. Treat as planning estimates, not committed budget.
Costs above are built from these verified unit-cost building blocks (sources cited in the canvas methodology section below):
| Line item | Verified cost | Source |
|---|---|---|
| Companies House — online incorporation | £50 | gov.uk (Feb 2026 fee increase) |
| Companies House — confirmation statement annual | £50 | gov.uk |
| ICO data protection fee Tier 1 | £52/yr | ico.org.uk |
| Domain .com first year | £8–£10 | Cloudflare / Namecheap 2026 pricing |
| Business email (one mailbox) | £12–£70/yr | Namecheap Private Email / Google Workspace |
| beehiiv — Scale tier (annual) | $43/mo ≈ £34/mo | beehiiv.com/pricing |
| Ahrefs Starter (new Jan 2026 entry tier) | $29/mo ≈ £23/mo | Ahrefs pricing 2026 |
| Stripe UK transaction fees | 1.5% + 20p (UK cards online) | stripe.com/gb/pricing |
| Stripe Atlas (contingent US LLC formation) | $500 one-time + $100/yr | stripe.com/atlas |
| UK ad-law / MHRA compliance review (one-off) Covers four UK frameworks — see below | £1,500–£2,500 flat-fee estimate | UK boutique ad-law solicitor norm (estimate — confirm via 30-min consult) |
| US healthcare attorney — AKS / medical-tourism structure review | $5,000–$15,000 flat-fee, ≈ £4,000–£12,000 | US boutique healthcare-law norm (estimate — Holt Law / LumaLex Law; confirm via 30-min consult) |
| Native ad test (Taboola minimum) | $50/day recommended ≈ £1,200/mo | Taboola self-serve minimums |
The £1,500–£2,500 line is not optional. It's the single piece of UK regulatory work that has to happen before any public-facing content goes live, because each of the four frameworks below can issue a takedown / enforcement action / fine independently:
| Framework | What it governs | Why it's compulsory for this venture family |
|---|---|---|
| CAP Code Committee of Advertising Practice |
UK non-broadcast advertising rules (web, social, email, print) | Health & Nutrition section is strict on what an information site can claim about compounds, protocols, practitioner outcomes. ASA enforces via takedowns + public rulings. |
| MHRA medicinal-claims rules Medicines and Healthcare products Regulatory Agency |
What counts as a "medicinal product" claim | Any "this substance treats/prevents/diagnoses disease" language turns the substance into an unlicensed medicine — instant MHRA exposure. Live precedent: Healthbio Ltd / methylene-blue ASA ruling 2025. |
| CPUTR 2008 Consumer Protection from Unfair Trading Regulations |
Paid-relationship disclosure + misleading-omission rules | Every affiliate link + sponsored placement + telehealth retainer relationship has to be disclosed in a CPUTR-compliant way, or both ASA and Trading Standards can act. |
| DPA 2018 / UK GDPR Data Protection Act + UK General Data Protection Regulation |
Personal data handling — lead capture, email lists, partner data sharing | Email lead capture + newsletter list + any partner-data sharing requires lawful basis, consent flows, retention policy, breach response plan. ICO can fine up to 4% of global turnover or £17.5m, whichever is higher. |
Output of the review: written compliance assessment flagging risks across all four frameworks, revised disclaimer + privacy + affiliate-disclosure templates, and one round of revisions. Sets editorial guardrails the content team uses for the life of the venture.